Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 7 (9), e016843

A Randomised Controlled Cross-Over Double-Blind Pilot Study Protocol on THC:CBD Oromucosal Spray Efficacy as an Add-On Therapy for Post-Stroke Spasticity

Affiliations
Randomized Controlled Trial

A Randomised Controlled Cross-Over Double-Blind Pilot Study Protocol on THC:CBD Oromucosal Spray Efficacy as an Add-On Therapy for Post-Stroke Spasticity

Lucio Marinelli et al. BMJ Open.

Abstract

Introduction: Stroke is the most disabling neurological disorder and often causes spasticity. Transmucosal cannabinoids (tetrahydrocannabinol and cannabidiol (THC:CBD), Sativex) is currently available to treat spasticity-associated symptoms in patients with multiple sclerosis. Cannabinoids are being considered useful also in the treatment of pain, nausea and epilepsy, but may bear and increased risk for cardiovascular events. Spasticity is often assessed with subjective and clinical rating scales, which are unable to measure the increased excitability of the monosynaptic reflex, considered the hallmark of spasticity. The neurophysiological assessment of the stretch reflex provides a precise and objective method to measure spasticity. We propose a novel study to understand if Sativex could be useful in reducing spasticity in stroke survivors and investigating tolerability and safety by accurate cardiovascular monitoring.

Methods and analysis: We will recruit 50 patients with spasticity following stroke to take THC:CBD in a double-blind placebo-controlled cross-over study. Spasticity will be assessed with a numeric rating scale for spasticity, the modified Ashworth scale and with the electromyographical recording of the stretch reflex. The cardiovascular risk will be assessed prior to inclusion. Blood pressure, heart rate, number of daily spasms, bladder function, sleep disruption and adverse events will be monitored throughout the study. A mixed-model analysis of variance will be used to compare the stretch reflex amplitude between the time points; semiquantitative measures will be compared using the Mann-Whitney test (THC:CBD vs placebo) and Wilcoxon test (baseline vs treatment).

Ethics and dissemination: The study was registered on the EudraCT database with number 2016-001034-10 and approved by both the Italian Medicines Agency (Agenzia Italiana del Farmaco) and local Ethics Committee 'Comitato Etico Regionale della Liguria'. Data will be made anonymous and uploaded to a open access repository. Results will be disseminated by presentations at national and international conferences and by publication in journals of clinical neuroscience and neurology.

Keywords: THC:CBD; cannabinoids; sativex; spasticity; stretch reflex; stroke.

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Graphical representation of the study protocol, particularly depicting the cross-over design and the time points. THC/CBD, tetrahydrocannabinol/cannabidiol.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology 2013;80:S13–S19.10.1212/WNL.0b013e3182762448 - DOI - PubMed
    1. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290–6.10.1111/j.1468-1331.2006.01639.x - DOI - PubMed
    1. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451–9.10.1179/016164109X12590518685660 - DOI - PubMed
    1. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex),as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122–31.10.1111/j.1468-1331.2010.03328.x - DOI - PubMed
    1. Etges T, Karolia K, Grint T, et al. An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex (THC:CBD, nabiximols) oromucosal spray. Ther Clin Risk Manag 2016;12:1667–75.10.2147/TCRM.S115014 - DOI - PMC - PubMed

Publication types

Feedback